House objects to Pfizer's Lipitor pitchman

I'm not a practicing doctor, nor do I play one on TV--but I did go to med school! Promise! That's what we imagine Dr. Robert Jarvik (photo) saying to Congress when questioned about his role as cholesterol drug pitchman for Pfizer. House Democrats are investigating whether consumers are misled by Jarvik's endorsement; though he invented the artificial heart, he has never practiced medicine.

So, Jarvik's now poster boy for a probe of DTC advertising. He "appears to be giving medical advice," but he's not qualified to do so, says Rep. John Dingell, chairman of a House subcommittee. But Pfizer maintains that Jarvik is well aware that patients need to take steps to protect their hearts--namely from high cholesterol, we assume--so they never need the kind of replacement he pioneered. What, we wonder, would Dingell have made of Marcus Welby, M.D.'s, pitch for Geritol?

- see the release from the House Committee on Energy and Commerce
- read the report from the International Herald Tribune

Related Articles:
Study: DTC ad spending on the rise. Report
10 reforms for drug advertising. Report
FDA to study TV drug ad imagery. Report

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.